BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » iPS Cells » Page 3

Century Therapeutics Launches With $250 Million for Allogeneic iPSC Platform

By

  • Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies

  • Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatments

July 01, 2019, LEVERKUSEN, Germany & PHILADELPHIA & TOKYO–Century Therapeutics, which was created by Versant Ventures as part of the firm’s core strategy to launch innovative biotech companies, emerged from stealth mode today with USD 250 million in financing commitments from Bayer, Versant and Fujifilm Cellular Dynamics Inc. (FCDI). The proceeds will enable Century to advance multiple programs into the clinic for hematologic and solid malignancies. [Read more…]

Interview With Kaz Hirao, CEO Of Cellular Dynamics International (CDI)

By

Cellular Dynamics International (CDI), a FUJIFILM company, is thCellular Dynamics FUJIFILM | Interview with Kaz Hirao, CEO of Cellular Dynamics International (CDI)e largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI recently divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics. As featured in the company motto, CDI is now positioned to facilitate “Endless Possibilities from Discovery to Regenerative Medicine.”

In this article:

[Read more…]

Development of iPSC-derived Disease Models

By

Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]

Celgene to Pay Evotec $9 Million as Companies Expand iPSC Collaboration

By

Hamburg, Germany, June 5, 2019 — Evotec SE announced that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $9.0 m to Evotec.

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one programme into lead optimisation as well as including additional cell lines and now a new cell type. [Read more…]

FUJIFILM CDI: A New Behemoth is Entering the Cell Therapy CDMO Market

By

A new behemoth is entering the cell therapy CDMO market, FUJIFILM Cellular Dynamics (FUJIFILM CDI). CDMOs are companies that provide manufacturing services to cell and gene therapy companies on a contract basis. In some cases, they may also support product development, clinical trial support, or commercial supply.

FUJIFILM Cellular Dynamics, Inc. (FCDI), a US subsidiary of FUJIFILM Corporation, will be spending $21M to open a new cGMP-compliant production facility in Madison, Wisconsin. According to FCDI’s January 2019 announcement, the facility will support FCDI’s internal cell therapeutics pipeline, as well as serve as a Contract Development and Manufacturing Organization (CDMO) for iPS cell products. [Read more…]

BioInformant's World-Class Clients